IN-VITRO INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS BY ASCORBIC-ACID

被引:12
|
作者
RAWAL, BD [1 ]
BARTOLINI, F [1 ]
VYAS, GN [1 ]
机构
[1] CTR TRASFUS E IMMUNOL TRAPIANTI,MILAN,ITALY
关键词
D O I
10.1016/1045-1056(95)90016-0
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In vitro inactivation of cell-free human immunodeficiency virus (CFHIV) was investigated by mixing replication-competent virions with aliquots of a culture medium (RPMI) containing increasing amounts (62.5-500 mu g/ml) of ascorbic acid (AA) at pH7. Similarly, mixtures of CFHIV and 500 mu g/ml AA in whole blood (WE) and leukocyte depleted blood (LDB) were made; control mixtures containing either CFHIV or AA alone in each experiment were included. After holding the mixtures for 3 h at 4 degrees C, the tubes containing WE and LDB mixtures were centrifuged to remove the blood cells. The respec tive supernatants, including the control aliquots, were layered over 0.5 x 10(6) MT2 cells in quadruplicate wells in microtitre plates. After 1 h of incubation at 37 degrees C in an atmosphere of 5.0% carbon dioxide to permit contact of viable virions, the fluid in each well was replaced with RPMI containing 20% fetal bovine serum (FBS). The incubation was then continued at 37 degrees C for 5 days. On the basis of (1) absence of syncytia formation, (2) 100% viability of MT2 cells as compared with the cell controls, (3) absence of p24 antigen in the culture supernates, and (4) absence of HIV DNA in MT2 cells, we conclude that 500 mu g/ml AA, in (a) RPMI, (b) WE, or (c) LDB, inactivated CFHIV in vitro. Furthermore, we determined that addition of 500 mu g/ml AA to platelet concentrates did not adversely affect the platelet function tests during 5 days of storage at room temperature. These data warrant further work to evaluate the mechanism of CFHIV inactivation by treatment of blood products with AA..
引用
收藏
页码:75 / 81
页数:7
相关论文
共 50 条
  • [41] HEPATITIS-C VIRUS MORE RESISTANT TO INACTIVATION THAN HUMAN-IMMUNODEFICIENCY-VIRUS
    MCAULEY, C
    HERRING, S
    UEMURA, Y
    YOKOYAMA, K
    NISHIMAKI, H
    YUNOKI, M
    VOX SANGUINIS, 1992, 63 (04) : 289 - 289
  • [42] ASCORBIC-ACID IN THE HUMAN STOMACH
    SOBALA, GM
    SCHORAH, CJ
    SANDERSON, M
    DIXON, MF
    TOMPKINS, DS
    GODWIN, P
    AXON, ATR
    GASTROENTEROLOGY, 1989, 97 (02) : 357 - 363
  • [43] ASCORBIC-ACID SUBSTITUTION IN HUMAN
    DEGKWITZ, E
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1972, 97 (20) : 811 - &
  • [44] ASCORBIC-ACID IN HUMAN NEUTROPHILS
    WASHKO, P
    ROTROSEN, D
    LEVINE, M
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 1991, 54 (06): : S1221 - S1227
  • [45] TRANSGLUTAMINASE COVALENTLY INCORPORATES AMINES INTO HUMAN-IMMUNODEFICIENCY-VIRUS ENVELOPE GLYCOPROTEIN GP120 IN-VITRO
    MARINIELLO, L
    ESPOSITO, C
    GENTILE, V
    PORTA, R
    INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, 1993, 42 (02): : 204 - 206
  • [46] INFLUENCE OF HUMAN-IMMUNODEFICIENCY-VIRUS NUCLEOCAPSID PROTEIN ON SYNTHESIS AND STRAND TRANSFER BY THE REVERSE-TRANSCRIPTASE IN-VITRO
    RODRIGUEZRODRIGUEZ, L
    TSUCHIHASHI, Z
    FUENTES, GM
    BAMBARA, RA
    FAY, PJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (25) : 15005 - 15011
  • [47] OPTIMAL INFECTIVITY IN-VITRO OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REQUIRES AN INTACT NEF GENE
    CHOWERS, MY
    SPINA, CA
    KWOH, TJ
    FITCH, NJS
    RICHMAN, DD
    GUATELLI, JC
    JOURNAL OF VIROLOGY, 1994, 68 (05) : 2906 - 2914
  • [48] CONSERVATION OF AN INTACT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VIF GENE IN-VITRO AND IN-VIVO
    SOVA, P
    VANRANST, M
    GUPTA, P
    BALACHANDRAN, R
    CHAO, W
    ITESCU, S
    MCKINLEY, G
    VOLSKY, DJ
    JOURNAL OF VIROLOGY, 1995, 69 (04) : 2557 - 2564
  • [49] RETENTION OF ASCORBIC-ACID IN PICKLES - EFFECT OF DIFFERENT SPICES AND SALT (AN IN-VITRO STUDY)
    SUREKHA, S
    BEGUM, K
    NAHRUNG-FOOD, 1993, 37 (06): : 596 - 601
  • [50] EFFECT OF DIFFERENT DONOR CELLS ON HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION AND SELECTION IN-VITRO
    SPIRA, AI
    HO, DD
    JOURNAL OF VIROLOGY, 1995, 69 (01) : 422 - 429